Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis

American Heart Journal

Volumn 131, Issue 1, 1996, Pages 1-6

  Sakata, Kazuyuki ^a   Miura, Fumiharu ^a   Sugino, Hiroshi ^a   Shinobe, Michitaka ^a   Shirotani, Manabu ^a   Yoshida, Hiroshi ^a   Mori, Noriko ^a   Hoshino, Tsuneo ^a   Takada, Akikazu ^b  

^a SHIZUOKA GENERAL HOSPITAL   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY OBSTRUCTION; EXERCISE TEST; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEART CATHETERIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030031680     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90043-5     Document Type: Article

References (30)

1. Holmes DR, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM, Van Raden MJ, Mock MB. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77c-81c.
2. Leimgruber PP, Roubin GS, Hollman J, Cotsonis GA, Meier B, Douglas JS, King SB III, Gruentzig AR. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986; 73:710-17.
3. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N, Horiuchi H, Ohishi H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616-23.
4. Kaltenbach M, Kober G, Scheber D, Vallbracht C. Recurrence rate after successful coronary angioplasty. Eur Heart J 1985;6:276-81.
5. Mechior JP, Meier B, Urban P, Finci L, Steffenino G, Noble J, Rutishauser W. Percutaneous transluminal coronary angioplasty for chronic total arterial occlusion. Am J Cardiol 1987;59:535-8.
6. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, De Feyter PJ, Van Den Brand M, Reiber JHC, Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon; a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988;77:361-71.
7. Faxon DP, Saborn TA, Weber VJ, Haudenschild C, Gottsman SB, McGovern WA, Ryan TJ. Restenosis following transluminal angioplasty in experimental atherosclerosis. Arteriosclerosis 1984;4:189-95.
8. Chesebro JH, Lam JYT, Badimon L, Fuster V. Restenosis after arterial angioplasty: a hemorrheologic response to injury. Am J Cardiol 1987;60:10B-6B.
9. Austin GE, Ratliff NB, Hollman J, Rabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-75.
10. Adams PC, Badimon JJ, Badimon L, Chesebro JH, Fuster V. Role of platelets in atherosclerosis: relevance to coronary arterial restenosis after angioplasty. In: Mehta JL, ed. Thrombosis and platelets in myocardial ischemia. Philadelphia: FA Davis, 1987:49-71.
11. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activation during angioplasty in humans. Circulation 1993;88:2728-34.
12. Haker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987;60:20-8B.
13. El-Tamimi H, Davies GJ, Hackett D, Fragasso G, Crea F, Maseri A, O'Sullivan C. Very early prediction of restenosis after successful coronary angioplasty: anatomic and functional assessment. J Am Coll Cardiol 1990;15:259-64.
14. Nobuyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim K. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol 1991;17:433-9.
15. Takada Y, Takada A. Measurements of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma. Thromb Res 1988;(suppl VIII):15-21.
16. Takada A, Shizume K, Ozawa T, Takahashi S, Takada Y. Characterization of various antibodies against tissue plasminogen activator using highly sensitive enzyme immunoassay. Thromb Res 1986;42:63-72.
17. Sakata K, Kurata C, Taguchi T, Suzuki S, Kobayashi A, Yamazaki N, Rydzewski A, Takada Y, Takada A. Clinical significance of tissue plasminogen activator inhibitor activity in patients with exercise-induced ischemia. AM HEART J 1990;120:831-8.
18. Sakata K, Hoshino T, Yoshida H, Ono N, Ohtani S, Yokoyama S, Mori N, Kaburagi T, Kurata C, Urano T, Takada Y, Takada A. Circadian fluctuations of tissue plasminogen activator antigen and plasminogen activator inhibitor-1 antigens in vasospastic angina. AM HEART J 1992;124:854-60.
19. Huber K, Jorg M, Probst P, Schuster E, Lang I, Kaindl F, Binder BR. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992;67:209-13.
20. Kirschstein W, Simianer S, Dempfle SE, Keller B, Stegaru B, Rentrop P, Heene DL. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty. Thromb Haemost 1989;62:772-5.
21. Hamsten A. The hemostatic system and coronary artery disease. Thromb Res 1993;70:1-38.
22. Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987;79:1749-55.
23. SchleefRR, Bevilacua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988;263:5797-803.
24. Speiser W, Anders BE, Binder BR, Berghaus GM. Method for the determination of fast acting plasminogen activator inhibitor capacity (PAI-CAP) in plasma, platelets and endothelial cells. Thromb Res 1986;44:503-15.
25. Fujii S, Hopkins WE, Sobel BE. Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation 1991;83:645-51.
26. Sawa H, Fujii S, Sobel BE. Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. Arterioscler Thromb 1992;12:1507-15.
27. Rogers C, Karnovsky MJ, Edelman ER. Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. Circulation 1993;88:1215-21.
28. Waller BF. Morphologic correlates of coronary angiographic patterns at the site of percutaneous transluminal coronary angioplasty. Clin Cardiol 1983;11:817-23.
29. Califf RM, Willerson JT. Percutaneous transluminal coronary angioplasty: prevention of occlusion and restenosis. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992:389-408.
30. Fanelli C, Aronoff R. Restenosis following coronary angioplasty. AM HEART J 1990;119:357-68.